BRKR:NGS-Bruker Corporation

EQUITY | Medical Diagnostics & Research | Nasdaq Global Select

Last Closing

USD 34.52

Change

+0.32 (+0.94)%

Market Cap

USD 3.67B

Volume

0.63M

Analyst Target

USD 34.85
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Bruker Corp is designer and manufacturer of life science & materials research systems in life science research, pharmaceuticals, applied markets, nanotechnology, cell biology, clinical research, microbiology & in-vitro diagnostics industries.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-01-18 )

Largest Industry Peers for Medical Diagnostics & Research

ETFs Containing BRKR

TYNE 12.61 % 0.00 %

N/A

N/A
FBT First Trust NYSE Arca Bio.. 0.00 % 0.57 %

-1.02 (0%)

USD 1.18B
QRH:CA 0.00 % 1.20 %

N/A

N/A
JSMD Janus Henderson Small/Mid.. 0.00 % 0.50 %

-0.54 (0%)

USD 0.36B
RNMC First Trust Mid Cap US Eq.. 0.00 % 0.60 %

-0.19 (0%)

USD 0.02B
KOMP SPDR Kensho New Economies.. 0.00 % 0.00 %

-0.25 (0%)

USD 1.91B
ZUH:CA BMO Equal Weight US Healt.. 0.00 % 0.39 %

-0.69 (0%)

CAD 0.32B
HLTH:AU VanEck Global Healthcare .. 0.00 % 0.00 %

N/A

USD 0.06B
FBT:LSE First Trust Global Funds .. 0.00 % 0.00 %

-16.10 (0%)

USD 6.45M
FBTU:LSE First Trust Global Funds .. 0.00 % 0.00 %

-0.23 (0%)

USD 6.45M

Market Performance

  Market Performance vs. Industry/Classification (Medical Diagnostics & Research) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 15.96% 60% D- 76% C+
Dividend Return N/A N/A N/A N/A F
Total Return 15.96% 60% D- 76% C+
Trailing 12 Months  
Capital Gain 0.76% 51% F 72% C
Dividend Return 0.47% 33% F 7% C-
Total Return 1.23% 51% F 68% D+
Trailing 5 Years  
Capital Gain 63.52% 56% F 73% C
Dividend Return 2.27% 50% F 6% D-
Total Return 65.80% 56% F 71% C-
Average Annual (5 Year Horizon)  
Capital Gain 12.90% 62% D 66% D+
Dividend Return 13.31% 62% D 63% D
Total Return 0.41% 50% F 11% F
Risk Return Profile  
Volatility (Standard Deviation) 21.41% 89% A- 61% D-
Risk Adjusted Return 62.16% 80% B- 69% C-
Market Capitalization 3.67B 90% A- 90% A-

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Diagnostics & Research) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 25.80 13% 6%
Price/Book Ratio 6.96 32% 14%
Price / Cash Flow Ratio 6.44 18% 13%
Price/Free Cash Flow Ratio 31.67 18% 14%
Management Effectiveness  
Return on Equity 12.67% 82% 74%
Return on Invested Capital 24.98% 90% 90%
Return on Assets 5.26% 82% 78%
Debt to Equity Ratio 35.50% 57% 56%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector